Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Body weight of 40 kg or more~* Established diagnosis of partial epilepsy for at least 1 year~* Current treatment with at least one and no more than two antiepileptics (AEDs)~* At least 6 episodes of simple partial motor seizures, complex partial seizures, or secondarily generalized seizures for 2 months (56 days) during the baseline period (No seizure free interval for more than 3 weeks)~Exclusion Criteria:~* Diagnosis of status epilepticus or epilepsia partialis continua within 6 months~* Patients with generalized epileptic syndrome~* Current or previous history of non-epileptic seizures, including psychogenic seizures~* Current or previous history of any serious or medically relevant systemic disease, including clinically apparent hepatic disease, renal failure, malignant neoplasm, insulin-requiring diabetes mellitus, or any disorder~* Patients with clinical evidence of significant cardiac disease~* Current or past (within 1 year) major significant psychotic disorder~* Have an ALT (GPT) greater than 1.5 times the upper reference limit or total bilirubin above the upper reference limit at screening laboratory tests

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 003 (Type: PLACEBO_COMPARATOR): Placebo tablet twice daily for 12 weeks
- 002 (Type: EXPERIMENTAL): RWJ-333369 200 mg tablet twice daily for 12 weeks
- 001 (Type: EXPERIMENTAL): RWJ-333369 100 mg tablet twice daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).